Jennerex, Inc.

SAN FRANCISCO, CA · CIK 0001525143 · Biotech · Acquired

Oncolytic virus immunotherapy (Pexa-Vec/JX-594) engineered to selectively replicate in and kill cancer cells while activating immune response

jennerex.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$5.4M
2 Form D · Oct 2011
180 months since last filing
Contracts
—
No federal contracts on record
Patents
4
1 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$3,630,146
Private capital raisedForm D · SEC$1,750,006
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1867Angarus Therapeutics, Inc.—$6.9M
1868Evoke Pharma Inc—$6.0M
1869Kiniksa Pharmaceuticals—$5.9M
1870Jennerex, Inc.—$5.4M
1871AKTTYVA THERAPEUTICS, INC.——
1872Oncolix, Inc.—$8.9M
1873COURAGE THERAPEUTICS INC—$4.5M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 16 related persons
  • Dr. John BellDirector
  • John BellDirector
  • Peter CharbonneauDirector
  • Helena ChayeExecutive Officer
  • Dr. Terry HermistonDirector
  • Hoyoung HuhDirector
  • David KirnDirector · Executive Officer
  • Lara LongpreExecutive Officer
  • Brennan MulcahyDirector
  • Martin MurphyDirector
  • Ken NewportDirector · Executive Officer
  • Gregory SchaferExecutive Officer
  • Barry ShermanDirector
  • Daniel SpiegelmanDirector
  • Dr. Hartley SternDirector
  • Ron VeredDirector

Patents

USPTO · 1 granted of 4
  • Methods and Compositions Concerning Poxviruses and Cancergranted
  • Oncolytic Vaccinia Virus Combination Cancer Therapyapplication
  • Oncolytic Vaccinia Virus Cancer Therapyapplication
  • Systemic Treatment Of Metastatic And/or Systemically-disseminated Cancers Using Gm-csf-expressing Poxvirusesapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.